Single-dose HPV vaccination schedule in Ivory Coast: position of the CNEIV-CI
DOI:
https://doi.org/10.4314/rasp.v7i1.2Keywords:
vaccination, HPV, single-dose, Côte d’IvoireAbstract
The Minister of Health requested the CNEIV-CI to obtain its opinion on adopting a single-dose HPV vaccination schedule in the EPI in Côte d'Ivoire. Such a vaccination schedule presents economic advantages for the country and mainly operational advantages for the EPI. The objective of our study was to clarify the opinion of the CNEIV-CI on the single-dose HPV vaccination schedule. A literature review was used to collect the evidence. After analysing the evidence on cancers induced by HR-HPV in Côte d'Ivoire, HPV genotypes circulating in the country, characteristics of the HPV vaccine, routine HPV vaccination coverage in Côte d'Ivoire, efficacy according to the HPV vaccination schedule (single dose or multi-dose), socioeconomic and ethical considerations, and programmatic and operational aspects, the CNEIV-CI recommended the single-dose HPV vaccination schedule in the EPI in Côte d'Ivoire. Strategies such as school vaccination and vaccination campaigns must be implemented to achieve 80 % minimum coverage for the HPV vaccine so that adopting this vaccination schedule is beneficial from a public health perspective. The successful implementation of these strategies requires raising awareness among parents because the target audience for the vaccine is adolescents whose parents are responsible for deciding on their vaccination.
References
Barnabas, V.R., Brown, R.E., Onono, A.M., Bukusi, A.E., Njoroge, B., Winer, L.R., & Mugo N., (2022). Efficacy of single-dose HPV vaccination among young African women. NEJM Evid., 1(5):EVIDoa2100056. doi: 10.1056/EVIDoa2100056
Brotherton, M.L.J., Budd, A., Rompotis, C., Bartlett, N., Malloy, J.M., Andersen, L.R., & Saville, M., (2019). Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. Papillomavirus Res., 8:100177. doi: 10.1016/j.pvr.2019.100177
Bruni, L., Albero, G., Serrano, B., Mena, M., Collado, J.J., Gómez, D., & de Sanjosé S., (2023). Human Papillomavirus and Related Diseases in Côte d’Ivoire. Summary Report. https://hpvcentre.net/statistics/reports/CIV.pdf
Burger, A.E., Campos, G.N., Sy, S., Regan, C., Kim, J.J., (2018). Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine, 36(32 Pt A):4823-4829. doi: 10.1016/j.vaccine.2018.04.061
CNEIV-CI, (2019). Recommandation du CNEIV-CI sur la vaccination contre le Papillomavirus humain.
De Martel, C., Plummer, M., Vignat, J., Franceschi, S., (2017). Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer, 141:664-670. doi: 10.1002/ijc.30716
Direction de Coordination du Programme Elargi de Vaccination. Plan d’introduction du vaccin antipaludique dans le Programme Elargi de Vaccination de Côte d’Ivoire, (2023). 59 p.
Direction de Coordination du Programme Elargi de Vaccination. Présentation de l’évolution des couvertures vaccinales HPV, (2023)
Goldie, J.S., O'Shea, M., Campos, G.N., Diaz, M., Sweet, S., Kim, S.Y., (2008). Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine, 26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053
Greer, E.C., Wheeler, M.C., Ladner, B.M., Beutner, K., Coyne, Y.M., Liang, H., & Ralston, R., (1995). Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol, 33(8):2058-2063. doi: 10.1128/jcm.33.8.2058-2063.1995
Kreimer, R.A., Sampson, N.J., Porras, C., Schiller, T.J., Kemp, T., Herrero, R. & Pinto, A.L., (2020). Evaluation of durability of a single dose of the bivalent HPV vaccine: The CVT trial. JNCI J Natl Cancer Inst, 112(10):djaa011. doi: 10.1093/jnci/djaa011
Ministère de la Santé, de l’Hygiène Publique et de la Couverture Maladie Universelle. (2023). Courrier 2185 du 23 mars
OMS. (2022b). Human Papillomavirus (HPV) vaccination coverage. Consulté le 15 mai 2023 ; récupéré à partir de l’adresse web <https://immunizationdata.who.int/pages/coverage/hpv.html?CODE=AFR&ANTIGEN=PRHPVC_F&YEAR=>
OMS. (2017). Vaccin contre les papillomavirus humains : note de synthèse de l’OMS, mai 2017. REH, 92(19):241-268
OMS. (2022a). Vaccins contre les papillomavirus humains : note de synthèse de l’OMS (mise à jour de 2022). REH, 97(50):645-672
Ouattara, A., Yéo, A., Blavo-Kouame, E.B., Koffi, T.F., Saraka, N.D., Faye-kette, H., & Dosso, M., (2017b). Humans Papillomavirus (Hpv) Infections in female sex workers in Côte d’Ivoire. AJCRR, 1(3):1-12. doi:10.28933/ajocrr-2017-11-2203
Ouattara, A., Yeo, A., Blavo-Kouame, E.B., Koffi, T.F., Saraka, N.D., Oura, P.K., & Dosso, M., (2017a). Detection of cervical human papillomavirus in women attending for cervical cancer screening by visual inspection in Côte d'Ivoire. J Cancer Res Exp Oncol, 9(2):7-15. doi: 10.5897/JCREO2017.0152
Public Health Resource Unit. (2006). Critical Appraisal Skills Programme (CASP): making sense of evidence. England. Consulté le 26 mai 2023 ; récupéré à partir de l’adresse web <http://www.pillole.org/public/aspnuke/downloads/documenti/strumentiappraisal.pdf>
SAGE. (2022a). Efficacy, effectiveness and immunogenicity of one dose of HPV vaccine compared with no vaccination, two doses, or three doses. Consulté le 26 mai 2023 ; récupéré à partir de l’adresse web https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Oct2019/5_session_HPV_vaccine/Oct2019_session5_final_one-dose-HPV.pdf
SAGE. (2022b). Strategic Advisory Group of Experts (SAGE) Working Group on potential contribution of HPV vaccines and immunization towards cervical cancer elimination. Consulté le 26 mai 2023 ; récupéré à partir de l’adresse web https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/human-papillomavirus-(hpv)/hpv-background-document--report-march-2022.pdf?sfvrsn=b600e252_1
Single Dose HPV Vaccine Evaluation Consortium. (2022). Review of the current published evidence for single-dose HPV vaccination. Consulté le 26 mai 2023 ; récupéré à partir de l’adresse web https://media.path.org/documents/20220328_SDHPV_Evidence_Review_Edition_4_Final_L2.pdf?_gl=1*am3vi8*_gcl_au*NDcyMTY0NTk5LjE3MjU2MTk5MDg.*_ga*ODg0Mjk3Nzk3LjE3MjU2MTk5MDg.*_ga_YBSE7ZKDQM*MTcyNTYxOTkwOC4xLjAuMTcyNTYxOTkwOC42MC4wLjA.
Smith, S.J., Gilbert, A.P, Melendy, A., Rana, K.R, Pimenta, M.J., (2011). Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health, 48(6): 540-52. doi: 10.1016/j.jadohealth.2011.03.010
Soheili, M., Keyvani, H., Soheili, M., Nasseri, S., (2021). Human papilloma virus : A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers. Med J Islam Repub Iran, 35:65. doi: 10.47176/mjiri.35.65
Sturegard, E., Johansson, H., Ekström, J., Hansson, B.G., Johnsson, A., Gustafsson, E., & Forslund, O., (2013). Human papillomavirus typing in reporting condyloma. Sex Transm Dis, 40:123-129. doi: 10.1097/OLQ.0b013e31827aa9b3
Vardas, E., Giuliano, R.A., Goldstone, S., Palefsky, M.J., Moreira, D.E., Penny, E.M. & Guris, D., (2011). External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. JID, 203(1):58-65. doi: 10.1093/infdis/jiq015
Watson-Jones, D., Changaluch, J., Whitworth, H., Pinto, L., Mutani, P., Indangasi, J. & Baisley, K., (2022). Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. Lancet Glob Health, 10(10): e1473-e1484. doi: 10.1016/S2214-109X(22)00309-6.
Whitworth, S.H., Gallagher, E.K., Howard, N., Mounier-Jack, S., Mbwanji, G., Kreimer, R.A. & Watson-Jones, D., (2020). Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine. 2020; 38(6):1302-1314. doi: 10.1016/j.vaccine.2019.12.017
World Health Organization. Strategic Advisory Group of Experts (SAGE) on Immunization Evidence to recommendations framework. Consulté le 26 mai 2023 ; récupéré à partir de l’adresse web <https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/human-papillomavirus-(hpv)/evidence-to-recommendation-table-1-dose-vs-2-dose.pdf?sfvrsn=eb11e290_1>
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Alfred Douba
This work is licensed under a Creative Commons Attribution 4.0 International License.
https://creativecommons.org/licenses/by/4.0/
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms